GPRC5d antibodies with enhanced effector function and uses thereof
GPRC5D antibodies with enhanced ADCC and CDC activities address the challenge of multiple myeloma relapses by improving effector functions, effectively inhibiting tumor growth.
AU2024394042A1Pending Publication Date: 2026-07-16JANSSEN BIOTECH INC
0 Cites 0 Cited by
Patent Information
- Application Number
- AU2024394042
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-12-08
- Filing Date
- 2024-12-06
- Publication Date
- 2026-07-16
AI Technical Summary
Technical Problem
Existing treatments for multiple myeloma, despite advancements, still experience relapses, necessitating the development of novel therapeutics with enhanced efficacy.
Method used
Development of GPRC5D antibodies with enhanced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities, utilizing specific CDR sequences and afucosylation to improve effector functions.
Benefits of technology
The antibodies demonstrate increased ADCC and CDC activities, effectively inhibiting multiple myeloma growth and proliferation, showing promise in preclinical tumor models.
✦ Generated by Eureka AI based on patent content.
Abstract
Herein are antibodies or antigen-binding fragments specifically binding to GPRC5D. Additionally, monovalent antibodies or antigen-binding fragments specifically binding to GPRC5D are also included. The Fc region of these antibodies contains K248E and T437R mutations (designated as "RE mutations") per the EU numbering system. The described antibodies, expressed in host cells that lack fucosylation capabilities, exhibit enhanced antibody¬ dependent cellular cytotoxicity (ADCC) and enhanced complement-dependent cytotoxicity (CDC).
Need to check novelty before this filing date? Find Prior Art